DEPICT Version 1
Research type
Research Study
Full title
Improving diagnosis, disease stratification and discovering biomarkers for progressive fibrosing lung disease: An observational cohort study.
IRAS ID
196923
Contact name
Toby Maher
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
5 years, 0 months, 2 days
Research summary
Interstitial lung diseases (ILDs) are responsible for approximately 15% of respiratory outpatient episodes and cause over 5000 deaths in the UK annually. Over 200 separate conditions give rise to interstitial abnormalities as a group.
The overall aim of this study is to collect blood and tissue samples from individuals with progressive interstitial lung disease to try and understand the disease mechanisms and identify novel disease markers. These markers may then be used in subsequent studies in order to provide proof of mechanism for potential new treatments. The results from this study will also be compared to data generated from other studies in patients with other associated ILD’s to try to identify the similarities and differences between these conditions. It is also planned to evaluate the use of daily spirometry and symptom diaries as tools for monitoring disease progression and for early detection of exacerbations. As such, this is an enabling study and will provide further insight into the natural history of fibrotic ILD and the pathogenesis of acute exacerbations.
REC name
London - Surrey Research Ethics Committee
REC reference
17/LO/1023
Date of REC Opinion
5 Jan 2018
REC opinion
Further Information Favourable Opinion